Corporate | 9 January 2013 07:29
Evotec AG / Key word(s): Alliance
09.01.2013 / 07:29
---------------------------------------------------------------------
Hamburg, Germany - 09 January 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that it has entered into a strategic
partnership with Yale University.
Under the agreement, Evotec and Yale intend to leverage first rate science
performed at Yale University together with Evotec's drug discovery
infrastructure and expertise into highly innovative discovery approaches in
diseases of high unmet medical need. Initially, Evotec and Yale have
defined a wide range of scientific fields including metabolic diseases,
CNS, immunological diseases and cancer where they will jointly assess and
potentially pursue novel assays, screens and models but in particular
exploratory drug targets and compounds. The intention is to seamlessly
integrate Evotec's drug discovery infrastructure with highly innovative
biology at Yale to mature individual projects to a stage where they can be
commercialised.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: 'We are
very excited about this open innovation alliance with Yale. There is a
tremendous wealth of scientific innovation at Yale that has the potential
to be directly translated into first- and best-in class drug candidates.
Together we want to significantly accelerate this process by removing
technical bottlenecks and focusing all efforts on bringing individual
projects to highest industrial standards in preparation for development and
commercialisation partnerships with Pharma companies.'
'This agreement is a new collaboration model between academia and the
pharmaceutical industry. It essentially gives all faculties at Yale the
opportunity to directly translate new biological insights into top notch
drug discovery projects. Evotec is uniquely suited as a partner as they
combine an extremely broad drug discovery platform with fast processes and
proven commercialisation skills', said Dr Jon Soderstrom, Managing Director
of Yale's Office of Cooperative Research.
No financials were disclosed.
ABOUT YALE
Founded in 1810, the Yale School of Medicine is a world-renowned centre for
biomedical research, education and advanced health care. Among its 27
departments are one of the nation's oldest schools of public health and the
internationally recognized Child Study Center, founded in 1911. Yale School
of Medicine consistently ranks among the handful of leading recipients of
research funding from the National Institutes of Health and other
organizations supporting the biomedical sciences. Its core faculty of more
than 1,100 physicians and scientists is well represented within the
Institute of Medicine and National Academy of Sciences and among
investigators of the Howard Hughes Medical Institute.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, MedImmune/Astra Zeneca, Novartis and Ono
Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and preclinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in
the field of Alzheimer's disease. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Dr Cord Dohrmann, Chief Scientific Officer, Phone: +49.(0)551.50558650,
cord.dohrmann@evotec.com
End of Corporate News
---------------------------------------------------------------------
09.01.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
198630 09.01.2013